M. Renn

RIG-I immunotherapy overcomes radioresistance in p53-positive malignant melanoma

This study shows that RIG-I ligands enhance radiation-induced tumor cell death and immunogenicity in melanoma, with p53 playing a key role in the synergy between RIG-I and radiation.

RIG-I-induced innate antiviral immunity protects mice from lethal SARS-CoV-2 infection

This study shows that activating the RIG-I receptor with synthetic RNA oligonucleotides before SARS-CoV-2 infection improves mouse survival and reduces viral load.